Bicocca Open Archive

Logo unimib boa
LUPPI, FABRIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.367
EU - Europa 3.387
AS - Asia 1.235
SA - Sud America 17
OC - Oceania 10
AF - Africa 9
Continente sconosciuto - Info sul continente non disponibili 3
Totale 13.028
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.237
IE - Irlanda 908
IT - Italia 887
CN - Cina 609
DE - Germania 492
SE - Svezia 473
HK - Hong Kong 437
GB - Regno Unito 201
UA - Ucraina 170
CA - Canada 114
FR - Francia 79
VN - Vietnam 66
FI - Finlandia 37
IN - India 29
DK - Danimarca 27
RU - Federazione Russa 26
TR - Turchia 25
AT - Austria 20
BE - Belgio 20
JP - Giappone 20
NL - Olanda 19
MX - Messico 16
SG - Singapore 10
BR - Brasile 8
PK - Pakistan 8
AU - Australia 6
CH - Svizzera 6
IR - Iran 6
MN - Mongolia 6
TW - Taiwan 5
AR - Argentina 4
KR - Corea 4
NZ - Nuova Zelanda 4
RO - Romania 4
CL - Cile 3
ES - Italia 3
EU - Europa 3
IL - Israele 3
MU - Mauritius 3
NG - Nigeria 3
BG - Bulgaria 2
CZ - Repubblica Ceca 2
MA - Marocco 2
MT - Malta 2
PT - Portogallo 2
SA - Arabia Saudita 2
AL - Albania 1
AM - Armenia 1
CO - Colombia 1
EG - Egitto 1
GR - Grecia 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LV - Lettonia 1
NO - Norvegia 1
PE - Perù 1
PH - Filippine 1
PL - Polonia 1
RS - Serbia 1
TH - Thailandia 1
YE - Yemen 1
Totale 13.028
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.515
Fairfield 1.223
Dublin 893
Wilmington 595
Woodbridge 518
Ashburn 506
Seattle 493
Chandler 474
Frankfurt am Main 442
Houston 441
Hong Kong 437
Cambridge 390
Princeton 370
New York 323
Dearborn 272
Milan 191
Altamura 158
Nanjing 154
Jacksonville 147
Lawrence 139
Beijing 83
Ottawa 76
San Diego 76
Andover 65
Shanghai 59
Rome 47
Dong Ket 46
Hebei 41
Boardman 39
London 39
Fremont 34
Nanchang 33
Shenyang 33
Helsinki 31
Guangzhou 30
Toronto 27
Jiaxing 23
Jinan 22
Monza 22
Norwalk 21
Tianjin 18
Vienna 18
Hefei 17
Kocaeli 17
Brussels 16
Changsha 15
Genoa 15
Chicago 14
Lissone 13
Ningbo 13
Redmond 10
Saint Louis 10
Carate Brianza 9
Bari 8
Falls Church 8
Castrolibero 7
Naples 7
Palermo 7
Zhengzhou 7
Brescia 6
Casorate Primo 6
Desio 6
Gallarate 6
Laurel 6
Pune 6
Washington 6
Bologna 5
Duncan 5
Edmonton 5
Faisalabad 5
Fuzhou 5
Groningen 5
Kunming 5
Lappeenranta 5
Lodi 5
New Bedfont 5
Taizhou 5
Turin 5
Acquafredda 4
Casier 4
Chiswick 4
Hangzhou 4
Hanoi 4
Leawood 4
Southampton 4
Taipei 4
Tokyo 4
Wuhan 4
Abano Terme 3
Abuja 3
Ankara 3
Auckland 3
Bonndorf 3
Buenos Aires 3
Catania 3
Coventry 3
Huizen 3
Kemerovo 3
Mariano Comense 3
Mexico City 3
Totale 10.935
Salva come PNG Salva come JPEG
Nome #
Progressive fibrosing interstitial lung diseases: prevalence and characterization in two Italian referral centers 273
Early referral to palliative care services in patients with IPF: A tool to take a step forward 263
Rehospitalization for pneumonia after first pneumonia admission: Incidence and predictors in a population-based cohort study 206
The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone 205
Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? 196
Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: The InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device) 175
Interstitial Pneumonia with Autoimmune Features: Why Rheumatologist-Pulmonologist Collaboration Is Essential 174
Janus-faced amiodarone-induced pneumopathy 168
Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature 163
Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis 160
A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis 158
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study 158
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 155
Clinical differences in sarcoidosis patients with and without lymphoma: A single-centre retrospective cohort analysis 148
Non-tuberculous mycobacteria pulmonary disease: an integrated approach beyond antibiotics 146
Functional Progression in Patients with Interstitial Lung Disease Resulted Positive to Antisynthetase Antibodies: A Multicenter, Retrospective Analysis 139
Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust 136
Cigarette smoke upregulates clusterin expression and apoptosis in human bronchial epithelial cells 132
Cigarette smoke extract (CSE) induces clusterion expression in human lung fibroblasts. 123
What patients with Idiopathic Pulmonary Fibrosis and caregivers want - Filling the currents gaps with patient reported outcomes and experience measures 118
Interstitial pneumonia with autoimmune features: A single center prospective follow-up study 117
Nintedanib and sildenafil in patients with idiopathic pulmonary fibrosis and right heart dysfunction: A prespecified subgroup analysis of a double-blind randomized clinical trial (instage) 115
Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study 114
Economic impact of anti-IL-5 agents in patients with severe eosinophilic asthma: A population-based cohort study 110
Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis 109
Diagnosis of asthma and copd 107
Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study 104
Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis 101
Management of Idiopathic Pulmonary Fibrosis 100
Management of fixed airflow limitation caused by asthma or chronic obstructive pulmonary disease 100
One-year pulmonary impairment after severe COVID-19: a prospective, multicenter follow-up study 100
Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis 98
Acute exacerbation of idiopathic pulmonary fibrosis: Lessons learned from acute respiratory distress syndrome? 96
Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dysfunction (Raynaud's phenomenon) in a case of early systemic sclerosis 96
Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review 94
"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease 94
Ventilatory support and mechanical properties of the fibrotic lung acting as a “squishy ball” 94
Analysis of pulmonary sounds for the diagnosis of interstitial lung diseases secondary to rheumatoid arthritis 93
Best supportive care for idiopathic pulmonary fibrosis: Current gaps and future directions 92
Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment 91
High serum levels of silica nanoparticles in systemic sclerosis patients with occupational exposure: Possible pathogenetic role in disease phenotypes 89
Interstitial pneumonitis with autoimmune features (IPAF): A work in progress 87
Effects of cigarette smoke condensate on proliferation and wound closure of bronchial epithelial cells in vitro: role of glutathione 87
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: A case report 86
Evaluation of serum (1 → 3)-β-d-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors 86
Multidisciplinary approach to systemic diseases: benefits for diagnosis and management of complex disorders 86
Molecular biomarkers in idiopathic pulmonary fibrosis: State of the art and future directions 85
Clinical performance of a commercial real-time PCR assay for Aspergillus DNA detection in serum samples from high-risk patients: comparison with a galactomannan enzyme immunoassay 85
Performance of tests for latent tuberculosis in different groups of immunocompromised patients 84
Bronchial hyperresponsiveness in asthmatic adults - A long-term correlation study 83
The Multiple Components of COPD 83
Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation 81
Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement 80
Pathophysiology of exacerbations of chronic obstructive pulmonary disease 79
Update in chronic obstructive pulmonary disease 2006 79
Mindfulness-based stress reduction in patients with interstitial lung diseases: A pilot, single-centre observational study on safety and efficacy 78
Sarcoidosis: challenging diagnostic aspects of an old disease 78
Effectiveness of pulmonary rehabilitation in patients with interstitial lung disease of different etiology: A multicenter prospective study 77
Update in chronic obstructive pulmonary disease 2005 77
Lung complications of Sjogren syndrome 77
Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline 77
Management of idiopathic pulmonary fibrosis 76
The big clinical trials in idiopathic pulmonary fibrosis 76
Differences between acute exacerbations of idiopathic pulmonary fibrosis and other interstitial lung diseases 76
Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia, A double-blind, randomised, placebo-controlled trial 76
Idiopathic pulmonary fibrosis mortality in the Italian epicenter of COVID-19 pandemic 75
Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases 75
Clusterin decreases oxidative stress in lung fibroblasts exposed to cigarette smoke 75
EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to egfr inhibitors 75
Definizione, classificazione ed eziopatogenesi 75
Pulmonary comorbidities associated with chronic obstructive pulmonary disease | [BPCO e altre malattie polmonari croniche] 74
Bradykinin-induced asthmatic fibroblast/myofibroblast activities via bradykinin B2 receptor and different MAPK pathways 74
Predicting the future of patients with idiopathic pulmonary fibrosis: another step forward 73
Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature 73
Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells 73
Complex chronic co-morbidities of COPD 72
Six-Month Pulmonary Impairment after Severe COVID-19: A Prospective, Multicentre Follow-Up Study 72
Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments 71
Non-steroid agents for idiopathic pulmonary fibrosis 71
To BAL or not to BAL: Is this a problem in diagnosing IPF? 70
Feasibility and clinical impact of a portable bi-level ventilation device in patients with severe chronic obstructive pulmonary disease and exertional dyspnea: preliminary results from a clinical series 70
A multidisciplinary approach to screen the post-COVID-19 conditions 69
Genetic testing in diffuse parenchymal lung disease 69
Clusterin (CLU) and lung cancer 69
Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows 69
The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19 69
Feasibility of CPAP application and variables related to worsening of respiratory failure in pregnant women with SARS-CoV-2 pneumonia: Experience of a tertiary care centre 69
Role Of The QFT-IT Assay For The Diagnosis Of Latent Tuberculosis Infection Among Adult Immigrants 68
Rheumatoid arthritis related interstitial lung disease 68
Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: A randomized noninferiority trial 68
Pulmonary Carcinosarcoma Arising in the Framework of an Idiopathic Pulmonary Fibrosis 66
Pathology of COPD and asthma 66
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis 66
Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation 65
Primary endpoints in phase 3 clinical trials in idiopathic pulmonary fibrosis: One step at a time 65
Treatment of chronic obstructive pulmonary disease and its comorbidities 64
Impact of N-acetyl-L-cysteine on SARS-CoV-2 pneumonia and its sequelae: results from a large cohort study 64
Effectiveness and economic impact of Dupilumab in asthma: a population-based cohort study 63
Smoking-related interstitial lung disease 63
Prognostic role of clusterin in resected adenocarcinomas of the lung 63
Totale 9.880
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.322
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.322
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019639 0 0 0 0 0 0 0 0 0 0 317 322
2019/20202.911 401 99 127 270 237 402 347 287 289 179 157 116
2020/20212.858 86 172 472 354 309 234 206 286 146 233 155 205
2021/20221.845 154 208 190 193 90 120 84 124 98 95 160 329
2022/20232.726 417 725 264 172 169 468 38 134 166 24 84 65
2023/20242.175 55 66 93 76 330 607 547 85 281 33 2 0
Totale 13.951